The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists

Annual Review of Pharmacology and Toxicology

Volumn 41, Issue , 2001, Pages 175-202

  Thibonnier, M ^a   Coles, P ^a   Thibonnier, A ^a   Shoham, M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aquaretics; Congestive heart failure; Dysmenorrhea; G protein coupled receptors; Hyponatremia; Liver cirrhosis; Nonpeptide antagonists; SIADH; Vasopressin receptors

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 7 CHLORO 5 HYDROXY 1 [2 METHYL 4 (2 METHYLBENZOYLAMINO)BENZOYL] 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPINE; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; RELCOVAPTAN; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST;

BRAIN EDEMA; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DYSMENORRHEA; HUMAN; NEPHROGENIC DIABETES INSIPIDUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; WATER RETENTION;

AMINO ACID SEQUENCE; ANIMALS; ARGININE VASOPRESSIN; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, VASOPRESSIN;

EID: 0035029158     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.41.1.175     Document Type: Review

References (106)

1. Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin
2. Molecular pharmacology of human vasopressin receptors
3. Edematous states: An overview
4. Hyponatremia: A prospective analysis of its epidemiology and the pathogenetic role of vasopressin
5. Vascular smooth muscle and neurohypophyseal hormones
6. Vasopressin in circulatory control and hypertension
7. Vasopressin as vasopressor
8. Regulation of pituitary ACTH secretion during chronic stress
9. Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors
10. 3 vasopressin receptor and the corticotroph phenotype in ectopic ACTH syndrome
11. Small molecule ligands for oxytocin and vasopressin receptors
12. 1-vascular vasopressin receptors
13. The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels
14. Wortmannin inhibits the activation of MAP kinase following vasopressin V1 receptor stimulation
15. Direct evidence for tyrosine and threonine phosphorylation and activation of mitogen-activated protein kinase, by vasopressin in cultured rat vascular smooth muscle cells
16. 1-vasculax vasopressin receptor
17. Arginine-vasopressin-induced hypertrophy of cultured rat aortic smooth muscle cells
18. Vasopressin receptor-mediated endocytosis in cells transfected with V1-type vasopressin receptors
19. Internalization, recycling, and redistribution of vasopressin receptors in rat hepatocytes
20. 2 vasopressin receptor
21. Transient phosphorylation of the V1a vasopressin receptor
22. Dynamic interaction of human/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation
23. 2 receptor in rat kidney
24. 2 vasopressin receptor by a plasma membrane metalloproteinase
25. 2 vasopressin receptor proteolytic cleavage
26. Congenital nephrogenic diabetes insipidus
27. The aquaporins, blueprints for cellular plumbing systems
28. Extrapituitaxy expression of the rat V1b vasopressin receptor gene
29. Molecular and functional characterization of V1b vasopressin receptor in rat adrenal medulla
30. 3-pituitary vasopressin receptor
31. Novel ligand specificity of pituitary vasopressin receptors in the rat
32. A novel type of vasopressin receptor on anterior pituitary corticotrophs?
33. Vasopressin potentiates cyclic AMP accumulation and ACTH release induced by corticotropin-release factor in rat anterior pituitary cells in culture
34. In vitro adrenocortico tropin/β-endorphin-releasing activity of vasopressin analogs is related neither to pressor nor to antidiuretic activity
35. Inositol phospholipid turnover and intracellular Ca++ responses to thyrotropin-releasing hormone, gonadotropin-releasing hormone and arginine vasopressin in pituitary corticotroph and somatotroph adenomas
36. Studies of the mechanisms of action of corticotropin-releasing factor (CRF) and vasopressin (AVP) in the ovine anterior pituitary: Evidence that CRF and AVP stimulate protein phosphorylation and dephosphorylation
37. Arginine vasopressin (AVP) causes the reversible phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein in the ovine anterior pituitary: Evidence that MARCKS phosphorylation is associated with adrenocorticotropin (ACTH) secretion
38. Pituitary receptors for corticotropin-releasing factor: No effect of vasopressin on binding or activation of adenylate cyclase
39. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis
40. Vasopressin-binding sites in the pig pituitary gland: Competition by novel vasopressin antagonists suggests the existence of an unusual receptor subtype in the anterior lobe
41. The human V3-pituitary receptor: Ligand-binding profile and density-dependent signaling pathways
42. Molecular endocrinology of the oxytocin receptor
43. Oxytocin stimulates mitogen-activated protein kinase activity in cultured human puerperal uterine myometrial cells
44. Multiple G proteins and phospholipase C isoforms in human myometrial cells: Implication for oxytocin action
45. 2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities
46. 2 vasopressin receptor
47. 2 receptor
48. Different single receptor domains determine the distinct G protein coupling profiles of members of the vasopressin receptor family
49. s coupling selectivity
50. 1-vascular vasopressin receptor in signal transduction
51. Folding and cell surface expression of the vasopressin V2 receptor: Requirement of the intracellular C-terminus
52. 2 receptor
53. 1 receptor antagonist
54. 1 receptor antagonist in mineralocorticoid hypertension in the rat
55. Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs
56. Vascular responses to vasopressin antagonists in man and rat
57. 1 receptor antagonist in humans
58. 1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on swiss 3T3 cells
59. Biochemical and pharmacological properties of SR49059, a new potent, non-peptide antagonist of rat and human vasopressin Vla receptors
60. 1a antagonist, on human vascular smooth muscle cells
61. 1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits
62. 1a vasopressin receptor antagonist
63. Effects of SR-49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans
64. Effects of the nonpeptide V1 vasopressin receptor antagonist SR49059 in hypertensive patients
65. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea
66. Receptor-mediated uterine effects of vasopressin and oxytocin in nonpregnant women
67. 1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions
68. 1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea
69. 2-receptor antagonist
70. Vasopressin V2-receptor antagonists: Panaceas for hyponatremia?
71. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
72. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
73. 2 receptor antagonist
74. 2 antagonist VPA-985 in rat caudal arteries and on arterial pressure in normotensive, SHR, and DOCA-salt hypertensive rats
75. 2 receptor vasopressin antagonist in patients with chronic heart failure
76. 2- receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
77. 2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats
78. Characterization of SR- 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist
79. Comparison of two aquaretic drugs (Niravoline and OPC-31260) in cirrhotic rats with ascites and water retention
80. Systemic and regional hemodynamic and biological effects of a new kappa-opioid agonist, niravoline, in healthy volunters
81. Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage
82. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants
83. Evidence against a pressor role for vasopressin in spontaneous hypertension
84. Attenuation of spontaneous hypertension in rats by a vasopressin antagonist
85. Endocrine control of salt and water excretion: The role of vasopressin in DOCA-salt hypertension
86. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo
87. 2 receptor antagonist (YM087) in the rat
88. Evaluation of the non-peptide, orally active, V1/V2 receptor antagonist YM087 in normal subjects
89. 2 vasopressin receptor antagonist in normal subjects
90. 1a receptor
91. 1 vascular vasopressin receptor
92. 1a vasopressin receptor
93. 1a vasopressin receptor fragments interfere with vasopressin binding via specific interaction with the receptor
94. 2 vasopressin receptors
95. Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor
96. 2 vasopressin receptor
97. Model for the structure of bacteriorhodopsin based on high-resolution electron cryomicroscopy
98. A molecular modeling and drug design program
99. Homology modelling, model and software evaluation: Three related sources
100. Accurate modeling of protein conformation by automatic segment matching
101. Molecular docking using surface complementarity